YM 244769

Na+/Ca2+ exchange inhibitor (reverse mode); neuroprotective CAS# 837424-39-2

YM 244769

Catalog No. BCC6222----Order now to get a substantial discount!

Product Name & Size Price Stock
YM 244769: 5mg $104 In Stock
YM 244769: 10mg Please Inquire In Stock
YM 244769: 20mg Please Inquire Please Inquire
YM 244769: 50mg Please Inquire Please Inquire
YM 244769: 100mg Please Inquire Please Inquire
YM 244769: 200mg Please Inquire Please Inquire
YM 244769: 500mg Please Inquire Please Inquire
YM 244769: 1000mg Please Inquire Please Inquire
Related Products
  • YM155

    Catalog No.:BCC2251
    CAS No.:781661-94-7

Quality Control of YM 244769

Number of papers citing our products

Chemical structure

YM 244769

3D structure

Chemical Properties of YM 244769

Cas No. 837424-39-2 SDF Download SDF
PubChem ID 90488952 Appearance Powder
Formula C26H24Cl2FN3O3 M.Wt 516.39
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO
Chemical Name N-[(3-Aminophenyl)methyl]-6-[4-[(3-fluorophenyl)methoxy]phenoxy]-3-pyridinecarboxamide dihydrochloride
SMILES C1=CC(=CC(=C1)N)CNC(=O)C2=CN=C(C=C2)OC3=CC=C(C=C3)OCC4=CC(=CC=C4)F.Cl.Cl
Standard InChIKey OCKIUNLKEPKCRE-UHFFFAOYSA-N
Standard InChI InChI=1S/C26H22FN3O3.2ClH/c27-21-5-1-4-19(13-21)17-32-23-8-10-24(11-9-23)33-25-12-7-20(16-29-25)26(31)30-15-18-3-2-6-22(28)14-18;;/h1-14,16H,15,17,28H2,(H,30,31);2*1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of YM 244769

DescriptionInhibitor of the reverse mode of Na+/Ca2+ exchange (NCX). Potently inhibits Na+-dependent 45Ca2+ uptake (IC50 values are 18, 68 and 96 nM for CCL39 cells transfected with NCX3, NCX1 and NCX2 respectively). Displays selectivity for NCX over other Na+ and Ca2+ transporters. Protects against hypoxia/reoxygenation-induced cell damage in neuronal SH-SY5Y cells expressing NCX1 and NCX3.

YM 244769 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

YM 244769 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of YM 244769

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.9365 mL 9.6826 mL 19.3652 mL 38.7304 mL 48.413 mL
5 mM 0.3873 mL 1.9365 mL 3.873 mL 7.7461 mL 9.6826 mL
10 mM 0.1937 mL 0.9683 mL 1.9365 mL 3.873 mL 4.8413 mL
50 mM 0.0387 mL 0.1937 mL 0.3873 mL 0.7746 mL 0.9683 mL
100 mM 0.0194 mL 0.0968 mL 0.1937 mL 0.3873 mL 0.4841 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on YM 244769

YM-244769, a novel Na+/Ca2+ exchange inhibitor that preferentially inhibits NCX3, efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage.[Pubmed:16973719]

Mol Pharmacol. 2006 Dec;70(6):2075-83.

We investigated the pharmacological properties and interaction domains of N-(3-aminobenzyl)-6-{4-[(3-fluorobenzyl)oxy]phenoxy} nicotinamide (YM-244769), a novel potent Na(+)/Ca(2+) exchange (NCX) inhibitor, using various NCX-transfectants and neuronal and renal cell lines. YM-244769 preferentially inhibited intracellular Na(+)-dependent (45)Ca(2+) uptake via NCX3 (IC(50) = 18 nM); the inhibition was 3.8- to 5.3-fold greater than for the uptake via NCX1 or NCX2, but it did not significantly affect extracellular Na(+)-dependent (45)Ca(2+) efflux via NCX isoforms. We searched for interaction domains with YM-244769 by NCX1/NCX3-chimeric analysis and determined that the alpha-2 region in NCX1 is mostly responsible for the differential drug response between NCX1 and NCX3. Further cysteine scanning mutagenesis in the alpha-2 region identified that the mutation at Gly833 markedly reduced sensitivity to YM-244769. Mutant exchangers that display either undetectable or accelerated Na(+)-dependent inactivation, had markedly reduced sensitivity or hypersensitivity to YM-244769, respectively. YM-244769, like 2-[2-[4-(4-nitrobenzyloxyl)phenyl]ethyl]isothiourea methanesulfonate (KB-R7943), protected against hypoxia/reoxygenation-induced cell damage in neuronal SH-SY5Y cells, which express NCX1 and NCX3, more efficiently than that in renal LLC-PK(1) cells, which exclusively express NCX1, whereas 2-[4-(4-nitrobenzyloxy)benzyl]thiazolidine-4-carboxylic acid ethyl ester (SN-6) suppressed renal cell damage to a greater degree than neuronal cell damage. These protective potencies consistently correlated well with their inhibitory efficacies for the Ca(2+) uptake via NCX isoforms existing in the corresponding cell lines. Antisense knockdown of NCX1 and NCX3 in SH-SY5Y cells confirmed that NCX3 contributes to the neuronal cell damage more than NCX1. Thus, YM-244769 is not only experimentally useful as a NCX inhibitor that preferentially inhibits NCX3, but also has therapeutic potential as a new neuroprotective drug.

Inhibitory effect of YM-244769, a novel Na(+)/Ca(2+) exchanger inhibitor on Na(+)/Ca(2+) exchange current in guinea pig cardiac ventricular myocytes.[Pubmed:27480939]

Naunyn Schmiedebergs Arch Pharmacol. 2016 Nov;389(11):1205-1214.

Recently, YM-244769 (N-(3-aminobenzyl)-6-{4-[(3-fluorobenzyl)oxy]phenoxy} nicotinamide) has been reported as a new potent and selective Na(+)/Ca(2+) exchange (NCX) inhibitor by using various cells transfected with NCX using the (45)Ca(2+) fluorescent technique. However, the electrophysiological study of YM-244769 on NCX had not been performed in the mammalian heart. We examined the effects of YM-244769 on NCX current (INCX) in single cardiac ventricular myocytes of guinea pigs by using the whole-cell voltage clamp technique. YM-244769 suppressed the bidirectional INCX in a concentration-dependent manner. The IC50 values of YM-244769 for the bidirectional outward and inward INCX were both about 0.1 muM. YM-244769 suppressed the unidirectional outward INCX (Ca(2+) entry mode) with an IC50 value of 0.05 muM. The effect on the unidirectional inward INCX (Ca(2+) exit mode) was less potent, with 10 muM of YM-244769 resulting in the inhibition of only about 50 %. At 5 mM intracellular Na(+) concentration, YM-244769 suppressed INCX more potently than it did at 0 mM [Na(+)]i. Intracellular application of trypsin via the pipette solution did not change the blocking effect of YM-244769. In conclusion, YM-244769 inhibits the Ca(2+) entry mode of NCX more potently than the Ca(2+) exit mode, and inhibition by YM-244769 is [Na(+)]i-dependent and trypsin-insensitive. These characteristics are similar to those of other benzyloxyphenyl derivative NCX inhibitors such as KB-R7943, SEA0400, and SN-6. The potency of YM-244769 as an NCX1 inhibitor is higher than those of KB-R7943 and SN-6 and is similar to that of SEA0400.

Na+/Ca2+ exchange inhibitors: a new class of calcium regulators.[Pubmed:17896959]

Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):188-98.

The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization. There are three mammalian NCX isoforms: NCX1 is widely expressed in the heart, kidney, brain, blood vessels, and so on; whereas the expression of NCX2 and NCX3 is limited mainly to the brain and skeletal muscle. The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996. Currently, experiments are actively progressing with more selective inhibitors: SEA0400, SN-6, and YM-244769. Intriguingly, the inhibitory potency of benzyloxyphenyl NCX inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation. Therefore, the benzyloxyphenyl inhibitors are apparently dormant during the forward mode under normal conditions (low Na(+)(i)), but become effective during the reverse mode under pathological conditions (high Na(+)(i)). This should be an ideal profile for calcium regulators against Na(+)(i)-related diseases, such as ischemia/reperfusion injuries, salt-dependent hypertension, and digitalis arrhythmia. Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action. It is possible that this property is partly responsible for their antiarrhythmic and cardioprotective effects. This article presents the characteristics of selective and non-selective NCX inhibitors and their therapeutic potential as a new calcium regulator.

Keywords:

YM 244769,837424-39-2,Natural Products,Na+/Ca2+ Exchanger, buy YM 244769 , YM 244769 supplier , purchase YM 244769 , YM 244769 cost , YM 244769 manufacturer , order YM 244769 , high purity YM 244769

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: